Comparison of Azathioprine and Mycophenolate Mofetil for the Prevention of Acute Rejection in Recipients of Pancreas Transplantation

• Published in: Journal of clinical pharmacology Vol. 41; no. 8; pp. 861 - 869
• Main Authors: Oh, Jung M., Wiland, Anne M., Klassen, David K., Weidle, Paul J., Bartlett, Stephen T.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01-08-2001; SAGE Publications; Sage Science; Wiley Subscription Services, Inc
• Subjects: Acute Disease; Adult; Azathioprine - therapeutic use; Biological and medical sciences; Female; Graft Rejection - prevention & control; Graft Survival; Humans; Immunomodulators; Immunosuppressive Agents - therapeutic use; Male; Medical sciences; Middle Aged; Mycophenolic Acid - analogs & derivatives; Mycophenolic Acid - therapeutic use; Pancreas Transplantation - immunology; Pancreas Transplantation - mortality; Pharmacology. Drug treatments; Survival Rate; Human; Mofetil; Prevention; Rejection; Chemotherapy; Mycophenolic acid; Acute; Transplantation; Immunosuppressive agent; Azathioprine; Pancreas; Comparative study
• ISSN: 0091-2700; 1552-4604
• DOI: 10.1177/00912700122010762

The study was performed to compare the efficacy and side effects of azathioprine (AZA) and mycophenolate mofetil (MMF) in conjunction with cyclosporine or tacrolimus and steroids for the prevention of acute pancreas rejection during the first 6 months of pancreas transplantation. In this case‐controlled study, MMF is compared with historical controls of AZA in the prevention of acute pancreas rejection. The primary measures of treatment efficacy were patient and pancreas survival rate at 6 months after transplantation. Secondary efficacy measures were the occurrence of biopsyproven pancreas rejections and the use of antilymphocyte preparations for rejection treatment. A total of 111 pancreas transplant patients (57 in the AZA group and 54 in the MMF group) were evaluated. The 6‐month patient survival rate was 96% in the AZA group versus 97% in the MMF group (p = 0.57). The 6‐month pancreas graft survival rate was 88% in the AZA group versus 91% in the MMF group (p = 0.29). However, biopsy‐proven rejection episodes during the first 6 months of transplantation were significantly lower with MMF (46%) than with AZA (69%) (p = 0.01). In addition, patients in the AZA group received a greater number of full courses of antilymphocyte therapy as a rejection treatment (p = 0.004). Overall, the frequency of adverse events was similar, although the MMF group experienced higher incidences of gastrointestinal adverse events. In conclusion, compared with AZA, MMF significantly reduces the rate of biopsy‐proven pancreas rejection during the first 6 months of transplantation and is well tolerated, except for gastrointestinal adverse events.